BA
TOVX icon

Bard Associates’s Theriva Biologics TOVX Stock Holding History

Bard Associates’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6
Closed -$13K – 177
2018
Q2 		$13K Hold
6
– – 0.01% 172
2018
Q1 		$18K Hold
6
– – 0.01% 170
2017
Q4 		$29K Sell
6
-2
-25% -$12.5K 0.01% 168
2017
Q3 		$62K Hold
8
– – 0.03% 167
2017
Q2 		$37K Hold
8
– – 0.02% 178
2017
Q1 		$43K Sell
8
-2
-20% -$14K 0.02% 176
2016
Q4 		$67K Sell
10
-1
-9% -$10.3K 0.03% 165
2016
Q3 		$160K Sell
11
-1
-8% -$15K 0.08% 152
2016
Q2 		$181K Hold
12
– – 0.1% 148
2016
Q1 		$248K Hold
12
– – 0.14% 132
2015
Q4 		$247K Sell
12
-1
-8% -$21.2K 0.15% 126
2015
Q3 		$258K Buy
+13
New +$320K 0.15% 125

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Bard Associates's TOVX Position: Q3 2018 in Review

Bard Associates sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 6 shares — an estimated $13K sold.

Bard Associates first reported a position in TOVX in Q3 2015 and held it in 12 quarters. The position peaked at $258K in Q3 2015. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

  • Bard Associates reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
  • Bard Associates sold 6 Theriva Biologics shares in Q3 2018, an estimated $13K.
  • Bard Associates first reported a position in Theriva Biologics in Q3 2015 and held it in 12 quarters.
  • Bard Associates's Theriva Biologics position peaked at $258K in Q3 2015.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Bard Associates's 13F filing for Q3 2018, filed 14 Nov 2018.